Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer and Eris P. Jordan, O.D., as Chief Development ...

Tachyus has announced a new contract with INEOS USA Oil & Gas (INEOS) to implement its Aurion platform. Aurion, a cloud-scalable solution, will aid INEOS in managing greenhouse gas (GHG) emissions, ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

Canadian miner Aurion Resources has entered into a definitive agreement with KoBold Exploration Finland, a subsidiary of KoBold Metals, for the exploration of critical minerals in Finland.

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO.

Leverages Alcon’s global scale with Aurion’s cell therapy expertise to accelerate U.S. Phase 3 development in fall of 2025 Aurion’s lead asset received Breakthrough Therapy Designation and ...

(RTTNews) - Aurion Resources Ltd. (AU.V) Wednesday has finalized an agreement with KoBold Exploration Finland Oy, a subsidiary of KoBold Metals Company, granting KoBold a 75% interest in a 35 km² ...

Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.

The leading eye-care company Alcon on Wednesday said it has acquired a majority stake in Aurion Biotech, capping months of legal wrangling over the future of the cell therapy developer.

Alcon Inc.'s strong growth, strategic acquisitions, and market leadership highlight its long-term potential. Read more on ALC ...

GENEVA, March 26, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a ...